Capricor Therapeutics (CAPR) Receivables - Net (2023 - 2024)

Capricor Therapeutics' Receivables - Net history runs 13 years deep, the most recent figure standing at $59167.0 for Q4 2025.

• In Q4 2025, Receivables - Net fell 99.43% year-over-year to $59167.0; the TTM figure through Dec 2025 stood at $59167.0 (down 99.43% YoY), while the FY2025 annual figure was $59167.0, down 99.43% from the prior year.
• Receivables - Net for Q4 2025 stood at $59167.0, roughly flat from $59167.0 in the prior quarter.
• The five-year high for Receivables - Net was $10.4 million in Q4 2023, with the low at $59167.0 in Q3 2025.
• The 5-year median for Receivables - Net is $400716.0 (2021), against an average of $1.5 million.
• The sharpest annual moves came in 2023 and 2025: Receivables - Net surged 1794.15% in 2023, then plunged 99.43% in 2025.
• Capricor Therapeutics' Receivables - Net stood at $391750.0 in 2021, then surged by 39.78% to $547580.0 in 2022, then soared by 1794.15% to $10.4 million in 2023, then fell by 0.03% to $10.4 million in 2024, then slumped by 99.43% to $59167.0 in 2025.
• Business Quant data shows CAPR's Receivables - Net at $59167.0 in Q4 2025, $59167.0 in Q3 2025, and $59509.0 in Q2 2025.